Skip to NavigationSkip to content

Systematic Review

Published date: 
07/12/2009

Therapy background

Vitamin K antagonists, such as warfarin, are commonly used in patients with coagulation problems. Their use is associated with frequent laboratory blood testing to measure coagulation levels, aiming to maintain a target range. Good anticoagulation control is important because variations in the target range could lead to ischaemic stroke (above target range) or a fatal clot (below target range).

Our client had developed an orally active, direct thrombin inhibitor with which, unlike vitamin K antagonists, there appeared to be no need for laboratory monitoring. Our client’s therapy potentially offered significant benefits to patients and cost-savings to the health system.

Abacus solution

In the first instance, Abacus conducted a systematic review which highlighted the issues surrounding established therapy. The results of this systematic review showed clearly:

With established therapy, in order to keep patients within a target range, frequent monitoring and dose adjustment were necessary. Patients were better controlled in certain environments (RCTs>Clinics>community).

This means that the efficacy of vitamin K antagonists could havebeen overestimated in the literature;

results from RCTs may represent the optimum achievable level of anticoagulation control comparedwith routine clinical practice. This highlights an opportunity for new therapies where frequent monitoring is not required to keep patients within target INR range. Outputs from the systematic review were used to develop a pharmacoeconomic (PE) model which compared the incremental costeffectiveness of our client’s therapy versus the established treatment. The model calculated the cost of treating a patient with the established therapy and the costs associated with anticoagulation monitoring to maintain a target range. This could then be compared with the costs of our client’s therapy without associated patient monitoring.

 

 

Business benefits

 

The systematic review and the PE model demonstrated that the client product, which did not require frequent laboratory monitoring of patients to keep them in designated INR range, had significant clinical and economic benefits over established therapy.

Outputs

Systematic Review (SR) and metaanalysis (MA) Publication in a peer reviewed journal of the SR and MA An economic model to support the economic case for adoption ofthe our client’s therapy

 

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches